These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10482480)

  • 21. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease.
    Whitcup SM; Salvo EC; Nussenblatt RB
    Am J Ophthalmol; 1994 Jul; 118(1):39-45. PubMed ID: 8023874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spectrum of Behçet's disease in the Indian population.
    Sachdev N; Kapali N; Singh R; Gupta V; Gupta A
    Int Ophthalmol; 2009 Dec; 29(6):495-501. PubMed ID: 18936879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
    Capella MJ; Foster CS
    Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
    Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
    Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behçet's syndrome: ocular features in an Australian population.
    Wakefield D; McCluskey P
    Aust N Z J Ophthalmol; 1990 May; 18(2):129-35. PubMed ID: 2390239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
    Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions].
    Sakane T; Mochizuki M; Inaba G; Masuda K
    Ryumachi; 1995 Oct; 35(5):802-13. PubMed ID: 8594659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching of anti-TNF-α agents in Behçet's disease.
    Furuta S; Chow YW; Chaudhry AN; Jayne D
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S62-8. PubMed ID: 23010387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy.
    Pacor ML; Biasi D; Lunardi C; Cortina P; Caramaschi P; Girelli D; Botto M; Urbani G; Lombardo G; Bambara LM
    Clin Rheumatol; 1994 Jun; 13(2):224-7. PubMed ID: 8088063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts.
    Khajehdehi P; Yip D; Bastani B
    Clin Transplant; 1999 Apr; 13(2):176-80. PubMed ID: 10202614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A ciclosporin A responsive case of Behçet's disease associated with IgA nephropathy].
    Suemitsu T; Saga T; Inui A; Ariizumi M; Shogi E; Sato H
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):189-94. PubMed ID: 8315882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of ultrasound biomicroscopy, indocyanine green angiography and HLA-B51 testing as adjunct methods in the appraisal of Behçet's uveitis.
    Klaeger AJ; Tran VT; Hiroz CA; Morisod L; Herbort CP
    Int Ophthalmol; 2004 Jan; 25(1):57-63. PubMed ID: 15085978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement?
    Akman-Demir G; Ayranci O; Kurtuncu M; Vanli EN; Mutlu M; Tugal-Tutkun I
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S84-90. PubMed ID: 19026121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose cyclosporin-A therapy in Behçet's disease.
    Sajjadi H; Soheilian M; Ahmadieh H; Hassanein K; Parvin M; Azarmina M; Ehyaee V; Amiransari B
    J Ocul Pharmacol; 1994; 10(3):553-60. PubMed ID: 7836864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.
    Kavandi H; Khabbazi A; Kolahi S; Hajialilo M; Shayan FK; Oliaei M
    Clin Rheumatol; 2016 Nov; 35(11):2765-2769. PubMed ID: 27234230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.